Multiple Myeloma: Evolving Therapies and Patient Well-Being
Noa Biran, MD, addresses unmet needs in relapsed/refractory multiple myeloma, focusing on reducing treatment burden and exploring fixed-duration therapies post-transplant, and highlights potential consolidation approaches with CAR-T cells or novel agents.
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
EP: 4.Examining Selinexor Role in RRMM Treatment
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
